A vaccine that overcomes scientific, funding, and R&D constraints and enters the market may still not become available to everybody who needs it. The public health goal of preventing or lessening disease through the administration of vaccines is not fulfilled at the point of market entrance. Rather, it requires that populations indicated for a particular vaccine are able to receive it. A separate dimension of investigating how well the vaccine innovation ecosystem functions is thus the problem of access to existing vaccines.